Lv63
2350 积分 2021-09-15 加入
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2个月前
已完结
Unlocking the potential of bispecific ADCs for targeted cancer therapy
2个月前
已完结
The present and future of bispecific antibodies for cancer therapy
2个月前
已完结
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
2个月前
已完结
Platform-based opportunities to streamline animal use in support of the 3Rs - recommendations from an antibody-drug conjugate analysis
2个月前
已完结
Strategies to reduce the use of non-human primates in development of oncology ADCs with cytotoxic payloads
2个月前
已完结
Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies
3个月前
已完结
Fifty years of monoclonals: the past, present and future of antibody therapeutics
3个月前
已完结
Determination of Antibody–Drug Conjugate Released Payload Species Using Directed in Vitro Assays and Mass Spectrometric Interrogation
3个月前
已完结
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
3个月前
已完结